196 related articles for article (PubMed ID: 35850914)
21. Splicing to Keep Cycling: The Importance of Pre-mRNA Splicing during the Cell Cycle.
Petasny M; Bentata M; Pawellek A; Baker M; Kay G; Salton M
Trends Genet; 2021 Mar; 37(3):266-278. PubMed ID: 32950269
[TBL] [Abstract][Full Text] [Related]
22. Defects in spliceosomal machinery: a new pathway of leukaemogenesis.
Maciejewski JP; Padgett RA
Br J Haematol; 2012 Jul; 158(2):165-173. PubMed ID: 22594801
[TBL] [Abstract][Full Text] [Related]
23. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
Dvinge H; Guenthoer J; Porter PL; Bradley RK
Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
[TBL] [Abstract][Full Text] [Related]
24. Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics.
Ogiya D; Chyra Z; Verselis SJ; O'Keefe M; Cobb J; Abiatari I; Talluri S; Sithara AA; Hideshima T; Chu MP; Hájek R; Dorfman DM; Pilarski LM; Anderson KC; Adamia S
Blood Cancer J; 2023 Feb; 13(1):23. PubMed ID: 36737429
[TBL] [Abstract][Full Text] [Related]
25. Roles and mechanisms of alternative splicing in cancer - implications for care.
Bonnal SC; López-Oreja I; Valcárcel J
Nat Rev Clin Oncol; 2020 Aug; 17(8):457-474. PubMed ID: 32303702
[TBL] [Abstract][Full Text] [Related]
26. Function, clinical application, and strategies of Pre-mRNA splicing in cancer.
Di C; Syafrizayanti ; Zhang Q; Chen Y; Wang Y; Zhang X; Liu Y; Sun C; Zhang H; Hoheisel JD
Cell Death Differ; 2019 Jul; 26(7):1181-1194. PubMed ID: 30464224
[TBL] [Abstract][Full Text] [Related]
27. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
28. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.
Wojtuszkiewicz A; Assaraf YG; Maas MJ; Kaspers GJ; Jansen G; Cloos J
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):673-89. PubMed ID: 25495223
[TBL] [Abstract][Full Text] [Related]
29. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
30. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Taylor J; Lee SC
Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
[TBL] [Abstract][Full Text] [Related]
31. Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.
Bielli P; Pagliarini V; Pieraccioli M; Caggiano C; Sette C
Cells; 2019 Dec; 9(1):. PubMed ID: 31861467
[TBL] [Abstract][Full Text] [Related]
32. RNA splicing dysregulation and the hallmarks of cancer.
Bradley RK; Anczuków O
Nat Rev Cancer; 2023 Mar; 23(3):135-155. PubMed ID: 36627445
[TBL] [Abstract][Full Text] [Related]
33. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
[TBL] [Abstract][Full Text] [Related]
34. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
35. Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression.
Adamia S; Kriangkum J; Belch AR; Pilarski LM
Adv Cancer Res; 2014; 123():67-94. PubMed ID: 25081526
[TBL] [Abstract][Full Text] [Related]
36. Mutational determinants of epigenetic instablity in myeloid malignancies.
Jankowska AM; Szpurka H
Semin Oncol; 2012 Feb; 39(1):80-96. PubMed ID: 22289495
[TBL] [Abstract][Full Text] [Related]
37. Pan-cancer analysis identifies mutations in
Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
[TBL] [Abstract][Full Text] [Related]
38. Mutations of RNA splicing factors in hematological malignancies.
Shukla GC; Singh J
Cancer Lett; 2017 Nov; 409():1-8. PubMed ID: 28888996
[TBL] [Abstract][Full Text] [Related]
39. RNA splicing, cell signaling, and response to therapies.
Abou Faycal C; Gazzeri S; Eymin B
Curr Opin Oncol; 2016 Jan; 28(1):58-64. PubMed ID: 26575690
[TBL] [Abstract][Full Text] [Related]
40. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
